In this retrospective study of treatment-naive PLWH initiating antiretroviral therapy, the score for the depression scale of the Patient Health Questionnaire (PHQ-9) was significantly higher at baseline (median, 6.0; interquartile range, 2-11) than at 12 months (3.0; 0-8; P < .001). Baseline depression and lack of insurance are associated with 12-month depression, but receipt of efavirenz-based antiretroviral therapy is not.
The prevalence of depression in persons living with human immunodeficiency virus (HIV) (PLWH) is >50% in some settings [1] . This has a profound impact on quality of life and HIV-related health outcomes [2] [3] [4] . Persons with comorbid HIV infection and depression have reduced rates of antiretroviral therapy (ART) adherence and higher rates of HIV progression and death [5] . Results from a clinical trial suggest that one antiretroviral agent, efavirenz, may increase depression and suicidality in PLWH [6] . As a result, efavirenz-containing ART regimens are no longer recommended for treatmentnaive PLWH in US guidelines. Observational data, however, have found no association between efavirenz and suicidality or death by suicide [7, 8] . The objective of the current study was to examine the association between sociodemographic and ART-specific factors and post-ART depression at 12 months in treatment-naive PLWH.
METHODS
In this retrospective observational follow-up study, we included treatment-naive PLWH starting ART between January 2007 and December 2012 at the HIV clinic associated with the University of Alabama at Birmingham. We queried our electronic database for sociodemographic factors, clinical characteristics, and Patient Health Questionnaire depression scale (PHQ-9) scores obtained before starting ART (baseline) and while receiving ART [9] . The PHQ-9 is a validated, self-administered depression screening tool, and scores correspond to mild (score, 5-9), moderate (10) (11) (12) (13) (14) , moderately severe (15) (16) (17) (18) (19) , or severe (≥20) depression [10] . Patients were dichotomized into "major" depression (score ≥10) and mild or no depression (score ≤9). New patients in our cohort have an orientation visit before their initial medical provider appointment, which includes an assessment of patient-reported outcomes, including depression, substance use, and high-risk alcohol use (with the PHQ-9, the Alcohol Use Disorder Identification Test-Consumption [AUDIT-C], and the Alcohol, Smoking, Substance Involvement Screening Test [ASSIST]) [11] [12] [13] . If patients report new, worsened, or severe depressive symptoms (including suicidal ideation), they are evaluated by the medical provider, a social worker, and, when indicated, a psychologist, such that a care plan is developed (ie, referral to the emergency department). Eligibility patients had a baseline PHQ-9 score available ≤ 365 days before ART initiation and a subsequent PHQ-9 score during a 12-month assessment window (value closest to 12 months and ≥4 weeks after starting ART). Both PHQ-9 assessments were obtained while patients were receiving the initial prescribed ART regimen.
We conducted univariate and multivariable logistic regression analyses to evaluate the relationship between 12-month depression and baseline demographic factors (race, sex, and insurance coverage), patient-reported outcomes (depression, alcohol use, and substance use), and ART composition ; the association was expressed as odds ratios (ORs) with 95% confidence intervals (CIs). Model performance was examined using the C statistic, maximum-rescaled R 2 , and the HosmerLemeshow test for model fit. Multicollinearity of the independent factors was examined with a variance inflation factor, which found no multicollinearity (variance inflation factor, <3.0 for all factors). When baseline and 12-month depression scores were compared with each other, we used paired analysis; when only 12-month depression was analyzed, we used unpaired analysis. We used the χ 2 test to compare differences in proportions of efavirenz versus non-efavirenz-based ART between patients meeting inclusion criteria (n = 281) and those who started ART in the study period but were excluded owing to missing PHQ-9 score at baseline or during the 12-month assessment window or who were lost to follow-up after ART initiation (n = 265). The cutoff for statistical significance was set at .05 (2 tailed); analyses were performed using SAS statistical software, version 9.3 (SAS Institute).
RESULTS

Comparison of Baseline Versus 12-Month Depression
Among 281 patients meeting eligibility criteria (mean age, 36 years; 83% male; 61% black; 61% men who have sex with men), 87 (30%) and 59 (21%) had depression at baseline and 12 months, respectively (Table 1) . Overall, PHQ-9 scores ere significantly higher at baseline (median, 6.0; interquartile range, 2-11) than at 12 months (3.0; 0-8; P < .001). For those receiving an efavirenz-based regimen (n = 136), the initial median PHQ-9 scores were 4.3 before ART and 2.0 after starting ART, compared with 8.0 and 4.0, respectively, among those receiving non-efavirenz-based regimens (n = 145). Among the 87 patients (30%) with baseline depression, 37 (44%) remained depressed after ART initiation. Irrespective of whether patients received efavirenz or another regimen, the odds of depression were higher at baseline than at 12 months (paired OR, 2.2; 95% CI, 1.3-3.6). In patients receiving an efavirenz-based regimen, depression was reported in 21% at baseline, compared with 18% at 12 months. For those receiving other regimens, depression was reported in 39% at baseline, compared with 24% at 12 months. A higher proportion of baseline depression in patients receiving other regimens than in those receiving efavirenz was indicative of channeling bias (adjusted in multivariable analysis).
Depression at 12 Months
In univariate analysis, depression at baseline and lack of insurance were significantly associated with depression at 12 months (Table 1) . Similarly, in multivariable analysis (Table 1) , the odds of depression was significantly higher in those reporting depression at baseline (adjusted OR, 8.1; 95% CI, 3.9-16.8; P < .001) and among those without insurance (2.6; 1.2-5.7). Older age was also associated with depression. No significant differences were found between efavirenz-and non-efavirenz-based regimens (adjusted OR, 0.9; 95% CI, .4-1.8).
Comparison With Excluded Individuals
There was no significant difference between those discontinuing efavirenz-based (33%) and non-efavirenz-based ART (34%) before the 12-month assessment window leading to exclusion from this study (P = .87). Among those excluded for all reasons, there was no difference in the proportions receiving efavirenzand non-efavirenz-based ART (53% and 47%, respectively) compared with those proportions (48% and 54%, respectively) among the whole study population (P = .26).
DISCUSSION
ART-naive PLWH in our clinic, as in others, have high rates of depression (30%), and ART initiation, regardless of composition, is associated with improved patient-reported depressive symptoms [1, 14] . These real-world findings underscore the myriad benefits of ART and suggests that efavirenz does not lead to significant increases in depressive symptoms for PLWH [1, 6] . Those without insurance and those with baseline depression were significantly more likely to have depression at 12 months. Results emphasize the need for comprehensive HIV care, including ART prescription and mental services for PLWH to optimize health outcomes.
Our results demonstrate a "channeling bias, " wherein PLWH with depressive symptoms were less likely to receive efavirenz, presumably owing to concerns for efavirenz-associated suicidality. It is noteworthy that treatment guidelines changed over the course of this study to include newer, efavirenz-free regimens. Subsequently, prescribing patterns changed, but efavirenz-based ART represented the greatest proportion of new prescriptions in each study year (based on prior analysis in this cohort) [15] . In addition, most PLWH in this cohort (67%) reached viral suppression before the regimen was discontinued or modified, which suggests relatively good adherence to initial ART, regardless of composition [15] . Efavirenz recipients were at lower odds of depression than those receiving a non-efavirenz-based regimen. After adjustment for bias in multivariable analysis, the difference in 12-month depression rates between recipients of efavirenz-based regimens and those receiving other ART regimens was negligible. Receipt of ART was associated with improvement in depression, irrespective of regimen.
The association of baseline depression with 12-month depression is not surprising, but highlights it an opportunity for mental health care at the outset of ART initiation. Although a majority had improved depressive symptoms with ART, 44% reported depressive symptoms at both ART initiation and 12 months-a risk factor for poor ART adherence, HIV progression, and death. Those without insurance also had greater odds of depression. This is interesting, because all PLWH in our clinic have access to medications and services owing to Ryan White Care Act federal "safety net" funds for the uninsured or underinsured. Thus, greater odds for depression in uninsured persons are unlikely to be related to a lack of medical or mental health care. Because these data were collected early in the Patient Protections and Affordable Care Act era, many of the "uninsured" patients in our study have since enrolled in insurance plans. Finally, insurance status may be serving as a proxy for socioeconomic status and identifying a relationship and unmeasured factors unrelated to health insurance enrollment per se.
Our study was limited by a modest sample size at a single, academic center. Because the analysis was limited to 12 months, we cannot make inferences regarding the relationship between long-term efavirenz therapy and depressive symptoms. Our clinic uses a multidisciplinary approach to managing mental health: psychotherapy, pharmacotherapy (eg, antidepressant medications), social services, and case management, which was not accounted for and could influence depressive symptoms.
This should not have disproportionately affected the efavirenz-based group. Of note, efavirenz is no longer a first-line ART regimen according to US guidelines, but many developing countries still rely on efavirenz for treatment-naive PLWH, and many treatment experienced PLWH in the United States are still receiving efavirenz [16] . c Post-ART depression was assessed at 12 months using the depression scale of the Patient Health Questionnaire (PHQ-9) and was categorized as major when the PHQ-9 score was ≥10 and as mild or none when the score was ≤9. Percentages represent row percentages. d Model performance as follows: C statistic, 0.801; maximum-rescaled R 2 = 28.6%; Hosmer-Lemeshow test, P = .61.
e ART including ≥ 3 antiretroviral agents and received for ≥14 days.
f Pre-ART depression was measured within 365 days before ART initiation.
g Statistically significant at P < .05.
h Estimates for the "unknown" categories are not shown (CD4 cell count, n = 47; alcohol use, n = 22; substance use, n = 17; transmission risk, n = 1).
i Assessed using the Alcohol Use Disorder Identification Test-Consumption (AUDIT-C) questionnaire. In summary, the reduced depressive symptoms observed after ART initiation is encouraging. Furthermore, the improved depressive symptoms observed during efavirenz-based therapy is reassuring, especially for treatment-experienced patients currently receiving efavirenz [16] . Our study also identified baseline depression and lack of insurance as risk factors for depression at 12 months. In addition to aggressive management of mental health comorbid conditions and insurance enrollment for all PLWH, research is needed to determine the relationships between ART composition, patient-reported outcomes, insurance status, and long-term depression. 
